PLEASANTON, CA --
NaviSite, Inc., a Time Warner Cable Company and premier provider of
enterprise-class hosting, managed applications, managed messaging and managed
cloud services , today announced the addition of 11 new Master Agents
to its growing partner roster: ChaseTek ,
Source , Glacier
Communications , One
Connect , Subsidium ,
and VGE .
Memory®, Inc. , (NYSE:VMEM), a leading
provider of award-winning all-flash storage arrays and appliances
delivering application solutions for the enterprise, today announced
that Kevin DeNuccio, President and Chief Executive Officer, will present
at the Barclays Global Technology Conference, to be held at The Palace
Hotel in San Francisco on Wednesday, December 10, 2014 at 11:40 am
- Third Quarter Diluted Earnings Per Share from Continuing Operations Were $1.20 in 2014, Compared to $1.25 in 2013, Reflecting Milder Third Quarter 2014 Temperatures
- Guidance Range for 2014 Diluted EPS from Continuing Operations Narrowed to $2.30 to $2.45 ST.
Epizyme, Inc., a clinical stage biopharmaceutical company creating
innovative personalized therapeutics for patients with genetically
defined cancers, today announced the publication on the website of the
American Society of Hematology (ASH) of an abstract entitled “The DOT1L
Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients
with MLL-Rearranged Leukemia”. The abstract contains preliminary data
from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of
the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed
for the treatment of acute leukemia with alterations in the MLL
gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD).
The Company plans to present updated data from the trial at the 56 th
annual meeting of ASH in San Francisco, Calif.
First Quarter Revenues of $280.1 Million, up 28.5% on a Reported Basis and up 28.1% on a Constant Currency Basis; Adjusted EBITDA up 20.7% on a Reported Basis and up 20.7% on a Constant Currency Basis; Company Updates Guidance, Announces Quarterly Dividend and Provides Supplemental Information
WESTLAKE, Texas , Nov.
Exelixis, Inc. (NASDAQ:EXEL) today announced that the enrollment target
of 650 patients has been reached for METEOR, the company’s phase 3
pivotal trial of cabozantinib in patients with metastatic renal cell
carcinoma (RCC) who have experienced disease progression following
treatment with at least one VEGFR tyrosine kinase inhibitor (TKI).
Top-line efficacy and safety data from METEOR are now expected in the
second quarter of 2015.
BANGALORE, India and SEATTLE , November 7, 2014 /PRNewswire/ --
Infosys, a global leader in technology, consulting, outsourcing and next-generation services, today announced a strategic partnership with Tableau Software (NYSE: DATA) , a global leader in rapid-fire, easy-to-use business analytics software.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.